UCB : Bimekizumab main stake for 2021
>2021: a year of top- and bottom-line growth - 2020 was a dynamic year for UCB in terms of revenue growth (+8% at constant currency (cc)). Even though the decline in profitability (EBITDA margin at 26.9% vs 29.1%) resulted in a virtually stable core EPS vs 2019 (-2% on a cc basis), ultimately, UCB fared better than its 2020 expectations. Above all, UCB proposes attractive 2021 targets that are above the consensus, with revenues of € 5.45-5.65bn and core EPS of between...UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.